Possible contribution of circulating interleukin-10 (IL-10) to anti-tumor immunity and prognosis in patients with unresectable hepatocellular carcinoma

Hepatology Research

Volumn 27, Issue 4, 2003, Pages 309-314

  Hattori, Etsuko ^a   Okumoto, Kazuo ^a   Adachi, Tohru ^a   Takeda, Tadashi ^a   Ito, Jun Itsu ^a   Sugahara, Kazuhiko ^a   Watanabe, Hisayoshi ^a   Saito, Koji ^a   Saito, Takafumi ^a   Togashi, Hitoshi ^a   Kawata, Sumio ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma (HCC); Lymphokine activated killer (LAK) activity; Natural killer (NK) activity; Prognosis

Indexed keywords

CYTOKINE; INTERLEUKIN 10;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; CANCER GRADING; CANCER STAGING; CELL ACTIVITY; CIRCULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENDER; HUMAN; IMMUNE DEFICIENCY; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LOGISTIC REGRESSION ANALYSIS; LYMPHOKINE ACTIVATED KILLER CELL; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PRIORITY JOURNAL; PROGNOSIS; RANK SUM TEST; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; TUMOR IMMUNITY;

EID: 0346895107     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hepres.2003.07.002     Document Type: Article

References (37)

1. Okuda K. Hepatocellular carcinoma: recent progress. Hepatology 1992;15:948-63.
2. Di Bisceglie AM. Hepatitis c and hepatocellular carcinoma. Seminar Liver Dis 1995;15:64-9.
3. Okuda K, Fujimoto I, Hanai A, Urano Y. Changing incidence of hepatocellular carcinoma in Japan. Cancer Res 1987;47:4967-72.
4. EI-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. New Engl J Med 1999;340:745-50.
5. Gastl G, Niederwiser D, Marth C, Huber H, Egg D, Schuler G, et al. Human large granular lymphocytes and their relationship to natural killer cell activity in various diseases state. Blood 1984;64:288-95.
6. Howard M, O'Garra A, Ishida H, et al. Biologic properties of interleukin-10. J Clin Immunol 1992;12:239-47.
7. Holland G, Zlotnik A. Interleukin-10 and cancer. Cancer Invest 1993;11:751-8.
8. Nabioullin R, Sone S, Mizuno K, et al. Interleukin-10 is a potent inhibitor of tumor cytotoxicity by human monocytes and alveolar macrophages. J Leukocyte Biol 1994;55:437-42.
9. Fortis C, Foppoli M, Gianotti L, et al. Increased interleukin-10 serum levels in patients with solid tumors. Cancer Lett 1996;104:1-5.
10. Merville P, Rousser F, Banchereau J, et al. Serum interleukin-10 in early stage multiple myeloma. Lancet 1992;340:1544-5.
11. Blay JY, Burdin N, Rousset F, et al. Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. Blood 1993;82:2169-74.
12. Chan G-Y, Wu C-W, Lui W-Y, Chang T-J, Kao H-L, Wu L-H, et al. Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 2000;231:552-8.
13. Kakumu S, Okumura A, Ishikawa T, et al. Serum levels of IL-10, IL-15 and soluble tumor necrosis factor-alpha (TNF-α) receptors in type C chronic liver disease. Clin Exp Immunol 1997;109:458-63.
14. Yamamoto M, Sugahara K. Overview of the general rules for clinical and pathological study of primary liver cancer in Japan. In: Tobe T, Kameda H, Okudaira M, et al., editors. Primary liver cancer in Japan. Tokyo: Springer; 1992. p. 385-92.
15. Pugh RWH, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
16. Infante RC, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhosis. Hepatology 1987;7:660-4.
17. Matsuda Y, Kawata S, Nagase T, Maeda Y, Yamasaki E, Kiso S, et al. Interleukin-6 in transcatheter arterial embolization for patients with hepatocellular carcinoma. Cancer 1994;73:53-7.
18. Rubin P, Pross HE, Rorder JC. Studies of human natural killer cells. II. Analysis at the single cell level. J Immunol 1982;128:2553-8.
19. Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K. Natural killer cell activity in patients with hepatocellular carcinoma. A new prognostic indicator after hepatectomy. Cancer 1998;83:58-63.
20. Kaplan E, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457-87.
21. Cacciarelli TV, Martinez OM, Gish RG, et al. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and post-treatment with interferon alfa. Hepatology 1996;24:6-9.
22. Kuzushita N, Hayashi N, Katayama K, Kanto T, Oshita M, Hagiwara H, et al. High levels of serum interleukin-10 are associated with a poor response to interferon treatment in patients with chronic hepatitis C. Scand J Gastroenterol 1997;32:169-74.
23. Edwards-Smith CJ, Jonsson JR, Purdie DM, Bansal A, Shorthouse C, Powell EE. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa. Hepatology 1999;30:526-30.
24. Yee JL, Tang J, Gibson AW, Kimberly R, Van Leeuwen DJ, Kaslow RA. Interleukin-10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology 2001;33:708-12.
25. Matsuguchi I, Okamura S, Kawasaki C, Niho Y. Production of interleukin-6 from human liver cell lines: production of interleukin-6 is not concurrent with the production of α-fetoprotein. Cancer Res 1990;50:7457-9.
26. Gastl GA, Abrams JS, Nanus DM, et al. Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. Int J Cancer 1993;55:96-101.
27. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, et al. High levels of transforming growth factor-β1 in patients with colorectal cancer. Association with disease progression. Gastroenterology 1996;110:375-82.
28. Yuen MF, Norris S. Expression of inhibitory receptors in natural killer (CD3(-) CD56(+)) cells and CD3(+) CD56 (+) cells in the peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with primary hepatocellular carcinoma. Clin Immunol 2001;101:264-9.
29. Kawarabayashi N, Seki S, Hatsuse K, et al. Decrease of CD 56 (+) T cells and natural killer cells in cirrhotic livers with hepatitis C may be involved in their susceptibility to hepatocellular carcinoma. Hepatology 2000;32:962-9.
30. Nakai T, Shimomura T, Hirokawa F. Spontaneous regression of current hepatocellular carcinoma after TAE: possible mechanisms of immune mediation. Int J Clin Oncol 2001;6:149-52.
31. Seo N, Tokura Y, Takigawa M, et al. Depletion of IL-10 and TGF-beta-producing regulatory gamma delta T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J Immunol 1999;163:242-9.
32. Sakaguchi E, Kayano K, Segawa M, Okamoto M, Sakaida I, Okita K. Th1 down-regulation at the single-lymphocyte level in HCV-related liver cirrhosis and the effect of TGF-α on Th1 response: possible implications for the development of hepatoma. Hepatol Res 2002;24:282-9.
33. Satoh H, Kobayashi K, Shima M, et al. Gene expression of interleukin-12 receptor β2 chain and Th1 population of peripheral blood mononuclear cells in chronic hepatitis C. Hepatol Res 2002;22:270-7.
34. Aoyagi Y, Mita Y, Suda T, et al. The fucosylation index of serum α-fetoprotein as useful prognosis factor in patients with hepatocellular carcinoma in special reference to chronological changes. Hepatol Res 2002;23:287-95.
35. Shimizu Y, Minemura N, Tsukishiro T, et al. Serum concentration of intercellular adhesion molecule-1 in patients with hepatocellular carcinoma is a marker of the disease progression and prognosis. Hepatology 1995;22:525-31.
36. Tsai JF, Jeng JE, Chung LY, et al. Elevated urinary transforming growth factor-β1 level as a tumor marker and predictor of poor survival in cirrhotic hepatocellular carcinoma. Br J Cancer 1997;76:244-50.
37. Kumagai N, Tsuchimoto K, Tsunematsu S, et al. Inhibition of growth of human hepatoma cells by dual-function antisense IL-6 oligonucleotides. Hetol Res 2002;22:119-26.